微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系

doi:10.3969/j.issn.1006-7795.2019.01.012

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (1): 65-71.doi: 10.3969/j.issn.1006-7795.2019.01.012

• 泌尿系统肿瘤：基础研究与临床实践 • 上一篇下一篇

微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系

王蔚^1,2, 苏嘉明³, 袁东波², 张伟², 陈卫红², 孙兆林², 朱建国^1,2

1. 贵州医科大学研究生院, 贵阳 550000;
2. 贵州省人民医院泌尿外科, 贵阳 550000;
3. 遵义医科大学研究生院, 贵州遵义 563000

收稿日期:2018-10-24 出版日期:2019-01-21 发布日期:2019-01-23
通讯作者: 朱建国 E-mail:doctorzhujianguo@163.com
基金资助:
国家自然科学基金（81660426，81873608），贵州省科技国际合作项目：黔科合平台人才（[2017]5803）。

Detection of MAP1A expression in prostate cancer and its clinical characteristics

Wang Wei^1,2, Su Jiaming³, Yuan Dongbo², Zhang Wei², Chen Weihong², Sun Zhaolin², Zhu Jianguo^1,2

1. Graduate School of Guizhou Medical University, Guiyang 550000, China;
2. Department of Urology, Guizhou Provincial People's Hospital, Guiyang 550000, China;
3. Graduate School of Zunyi Medical University, Zunyi 563000, Guizhou Province, China

Received:2018-10-24 Online:2019-01-21 Published:2019-01-23
Supported by:
This study was supported by National Natural Science Foundation of China (81660426, 81873608), Guizhou Science and Technology International Cooperation Project ([2017] 5803).

摘要/Abstract

摘要： 目的探讨微管相关蛋白1A（microtubule associated protein 1A，MAP1A）在前列腺癌中的表达与其临床特征的关系。方法通过免疫组织化学（immunohistochemistry，IHC）染色检测人前列腺癌组织和非癌前列腺组织中MAP1A蛋白质的表达水平，应用实时荧光定量聚合酶链式反应（quantitative real-time polymerase chain reaction，RT-qPCR）检测MAP1A基因在前列腺癌与正常前列腺组织中mRNA的表达差异，进一步使用癌症基因信息数据库（the Cancer Genome Atlas，TCGA）统计分析MAP1A基因表达水平与前列腺癌患者的临床病理学特征之间的关联。结果免疫组化染色结果分析显示，与癌旁正常组织相比，前列腺癌组织中MAP1A的蛋白表达显著降低[免疫组化染色评分（immunoreactive score，IRS）：前列腺癌组织为4.08±1.58，癌旁正常组织为4.91±1.46（P<0.001）]。MAP1A在前列腺癌及癌旁正常组织中的阳性表达率分别为58.6%和82.7%，两者差异具有统计学意义（χ²=12.225，P=0.001）。使用RT-qPCR检测MAP1A mRNA表达，发现其在前列腺癌中表达显著低于正常前列腺组织（P=0.019）。通过对TCGA数据库进行分析，笔者发现MAP1A在不同临床特征的肿瘤组织中的表达差异具有统计学意义，如患者Gleason评分（P<0.001），临床病理分期（P=0.009），是否转移（P=0.008），总体生存率（P=0.049）。结论 MAP1A在前列腺癌中表达下调且与肿瘤组织的分期有关，分期越晚，MAP1A的表达越低，这提示其可能参与了前列腺癌的发生、发展。

关键词: 前列腺癌, 微管相关蛋白1A, 临床特征

Abstract: Objective To investigate the expression of MAP1A in prostate cancer and its relationship with clinical features. Methods The expression of MAP1A at the protein level in human prostate cancer and non-cancerous prostate tissue was detected with immunohistochemistry, and it was further validated with quantitative real-time polymerase chain reaction (RT-qPCR) at the mRNA level. Subsequently, the association of MAP1A expression with the clinical characteristics of the patients with prostate cancer was statistically analyzed with the Cancer Genome Atlas (TCGA) database. Results Immunohistochemistry stains showed that the protein expression of MAP1A was significantly decreased in prostate cancer tissues compared with adjacent normal tissues[immunoreactive score (IRS):Prostate cancer tissue=4.08±1.58,Tumor-adjacent normal tissue=4.91±1.46,P<0.001]. The positive expression rates of MAP1A in PCa tissue samples and adjacent normal tissue samples were 58.6% and 82.7%, respectively, indicating a statistically significant difference (χ²=12.225,P=0.001). MAP1A mRNA expression was detected with quantitative real-time PCR and it was significantly lower in prostate cancer than in normal prostate tissue (P=0.019). Analysis of TCGA data suggested, that the expression of MAP1A is significantly different in the tumor tissues with different clinical characteristics, such as Gleason score (P<0.001), clinical pathological stage (P=0.009), metastasis (P=0.008), and overall survival rate (P=0.049). Conclusion MAP1A is down-regulated in prostate cancer and is associated with the staging of tumor tissue. The later stage of tumor tissue, the lower the expression of MAP1A, suggesting that MAP1A is related to the development and progression of prostate cancer.

Key words: prostate cancer(PCa), microtubule associated protein 1A(MAP1A), clinical characteristics

中图分类号:

R737.25

王蔚, 苏嘉明, 袁东波, 张伟, 陈卫红, 孙兆林, 朱建国. 微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J]. 首都医科大学学报, 2019, 40(1): 65-71.

Wang Wei, Su Jiaming, Yuan Dongbo, Zhang Wei, Chen Weihong, Sun Zhaolin, Zhu Jianguo. Detection of MAP1A expression in prostate cancer and its clinical characteristics[J]. Journal of Capital Medical University, 2019, 40(1): 65-71.

参考文献

[1] Wong M C, Goggins W B, Wang H H, et al. Global incidence and mortality for prostate cancer:analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5):862-874.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[4] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[5] Gerhauser C, Favero F, Risch T, et al. Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories[J].Cancer Cell,2018,34(6):996-1011.
[6] Wedge D C, Gundem G, Mitchell T, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets[J].Nat Genet, 2018,50(5):682-692.
[7] Cucchiara V, Cooperberg M R, Dall'Era M, et al. Genomic markers in prostate cancer decision making[J].Eur Urol,2018,73(4):572-582.
[8] Halpain S, Dehmelt L. The MAP1 family ofmicrotubule-associated proteins[J]. Genome Biol, 2006, 7(6):224.
[9] Chu J, Li N,Gai W. Identification of genes that predict the biochemical recurrence of prostate cancer[J]. Oncol Lett, 2018, 16(3):3347-3452.
[10] Canes D. Prostate cancer:Determining optimal therapy of early-stage disease remainscomplicated[J]. Nat Rev Urol, 2016, 13(12):703-704.
[11] McPhail S, Johnson S, Greenberg D, et al. Stage at diagnosis and early mortality from cancer in England[J]. Br J Cancer, 2015, 112:S108-S115.
[12] 马悦,陈弋生. 前列腺癌精准诊断的新进展[J]. 中华男科学杂志, 2016, 22(11):1030-1033.
[13] 张振奇,刘桂丽,夏小彬,等.血清PHI和尿PCA3联合检测评分对PSA灰区前列腺癌诊断价值探讨[J].中华肿瘤防治杂志,2018,25(5):329-333.
[14] 赖亚明,韩斌,吴斌.Gleason评分对前列腺癌转归预测意义[J].中华肿瘤防治杂志,2018,25(13):951-955.
[15] Thompson I M,Pauler D K,Goodman P J,et al.Prevalence of prostate cancer among men with a prostate specific antigen level[16] Mistry K,cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma[J].J Am Board Fam Pract,2003,16(2):95-101.
[17] 年新文,任善成,许传亮. 前列腺癌早期诊断标志物的研究进展[J]. 临床泌尿外科杂志,2016,31(9):852-855.
[18] Kazzazi A, Momtahen S, Bruhn A, et al. New findinfs in localized and advanced prostate cancer:AUA 2011 review[J]. Can J Urol, 2011,18(3):5683-5688.
[19] Litwin M S, Tan H J. The diagnosis and treatment of prostate cancer:a review[J]. JAMA, 2017, 317(24):2532-2542.
[20] Helgstrand J T, Roder M A, Klemann N, et al. Diagnostic characteristics of lethal prostate cancer[J]. Eur J Cancer, 2017,84:18-26.
[21] Li S, Ma Y, Xie C, et al. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression[J]. Oncotarget, 2015, 6(26):22587-22597.
[22] Kendel F, Helbig L, Neumann K, et al. Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy[J]. Int J Cancer., 2016, 139(4):749-753.
[23] 冯思坛,施鑫. 微管相关蛋白与肿瘤关系的研究进展[N]. 医学研究生学报, 2013,26(8):878-881.
[24] Fink J K, Jones S M, Esposito C,et al. Human microtubule-associated protein 1a (MAP1A) gene:genomic organization, cDNA sequence, and developmental-and tissue-specific expression[J]. Genomics, 1996, 35(3):577-585.
[25] Liu Y, Lee J W, Ackerman S L,et al. Mutations in the microtubule-associated protein 1A (Map1a) gene cause Purkinje cell degeneration[J].J Neurosci,2015,35(11):4587-4598.
[26] Meyer M A. Highly expressed genes in human high grade gliomas:immunohistochemical analysis of data from the human protein atlas[J]. Neurol Int, 2014, 6(2):5348.
[27] Knutson T P, Daniel A R, Fan D,et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression[J]. Breast Cancer Res, 2012, 14(3):R95.
[28] Jiang X, Zhong W, Huang H,et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients[J]. Mol Carcinog, 2015, 54(10):1194-1204.

微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系

Detection of MAP1A expression in prostate cancer and its clinical characteristics

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贾静, 陈文明, 李燕郴. 多发性骨髓瘤伴中枢侵犯临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(1): 161-166.
[2]	张静涛, 王欣然, 韩斌如, 强莹, 刘雪琪, 张毅. 老年肺癌患者胸腔镜肺切除术后并发心律失常的临床特征及危险因素分析[J]. 首都医科大学学报, 2022, 43(4): 564-569.
[3]	刘珊珊, 房萌, 朱虹, 尹冬青, 赵燕, 赵爽, 贾竑晓. 2010年和2019年双相情感障碍住院患者的临床特征和未治疗持续时间的因素分析[J]. 首都医科大学学报, 2022, 43(3): 415-420.
[4]	邵琳琳, 朱思莹, 邢洁, 武珊珊, 朱圣韬, 张澍田. 原发性胃肠道淋巴瘤的临床特征和内镜特点分析[J]. 首都医科大学学报, 2022, 43(2): 205-209.
[5]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[6]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[7]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.
[8]	詹敏敏, 马慧萱, 康雪纯, 鲁新亮, 宫淑婷, 邹琦, 吕继辉, 周爱红, 贾建平, 魏翠柏. 轻中度阿尔茨海默病患者精神行为学症状特点及关联性分析[J]. 首都医科大学学报, 2021, 42(3): 354-359.
[9]	岳晓艳, 李凤杰, 蒋志锋, 朱娅楠. 慢性阻塞性肺疾病急性加重合并下肢深静脉血栓的临床特征及危险因素[J]. 首都医科大学学报, 2021, 42(1): 153-157.
[10]	樊笑琪, 刘志斌, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 邢念增, 牛亦农. 腹腔镜单纯尿道前壁加强法与尿道前后壁加强法(Sandwich法)改善前列腺癌根治术后早期尿控的对比分析[J]. 首都医科大学学报, 2020, 41(4): 542-546.
[11]	白志杰, 王新胜, 马洪顺, 李波. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J]. 首都医科大学学报, 2020, 41(4): 631-635.
[12]	张维, 侯维, 李侗曾, 李爱新, 潘闻, 金荣华, 梁连春, 胡中杰. 74例新型冠状病毒肺炎临床特征分析[J]. 首都医科大学学报, 2020, 41(2): 161-167.
[13]	谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系[J]. 首都医科大学学报, 2020, 41(1): 103-107.
[14]	赵丽东, 杨林花. 30例血栓性血小板减少性紫癜临床分析[J]. 首都医科大学学报, 2019, 40(3): 454-457.
[15]	平浩, 马林祥, 王明帅, 龙军, 牛亦农, 刘跃新, 邢念增. 单羧酸转运蛋白4(MCT4)在前列腺癌中的表达及调控研究[J]. 首都医科大学学报, 2019, 40(1): 59-64.